April 8, 2019
Azitra Demonstrates Feasibility of Engineering the Skin Microbiome to Treat Serious Skin Conditions
Azitra will be presenting results from the joint researchshowing the successful genetic engineering of the common skin bacterium, Staphylococcusepidermidis, to produce high levels of functional LEKTI protein, aprotease inhibitor involved in regulating the rate of skin loss.